Table 1.
Qualitative and quantitative computed tomography features of pancreatic neuroendocrine tumours according to the World Health Organization tumour classification.
| Threshold criterion | Grade 1 (n=19) | Grade 2 (n=20) | p-Value |
|---|---|---|---|
| Mean tumour size | 15.2±4.7 | 30.2±17.3 | 0.002 |
| Tumour contrast enhancement | |||
| Arterial phase | 147±45 | 104.2±39.4 | 0.004 |
| Venous phase | 107.9±26.2 | 93.3±23 | NS |
| Delayed phase | 78.5±18.5 | 71.4±15.6 | NS |
| Tumour-to-pancreas contrast ratio | |||
| Arterial phase | 1.53±0.45 | 1.01±0.33 | 0.0003 |
| Venous phase | 1.29±0.32 | 1.03±0.13 | 0.01 |
| Delayed phase | 1.14±0.27 | 1.06±0.13 | NS |
| Contrast enhancement pattern | |||
| Type A | 17 | 6 | 0.001 |
| Type B | 2 | 14 | |
| Homogeneity | |||
| Homogeneous | 16 | 13 | NS |
| Non-homogeneous | 3 | 7 | |
| Tumour delineation | |||
| Clear | 18 | 15 | NS |
| Non-clear | 1 | 5 | |
| Upstream pancreatic duct dilatation | |||
| Present | 1 | 2 | NS |
| Absent | 18 | 18 | |
| Cystic or necrotic change | |||
| Present | 3 | 5 | NS |
| Absent | 16 | 15 | |
| Calcifications | |||
| Present | 2 | 3 | NS |
| Absent | 17 | 17 | |
| Liver metastases | |||
| Present | 0 | 3 | NS |
| Absent | 19 | 17 | |
NS, non-significant.